Latest Dana-Farber Cancer Institute Stories
Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.
A group of small molecules called EETs – currently under scrutiny as possible treatment targets for a host of cardiovascular diseases – may also drive the growth and spread of cancer.
In an African county lacking any specialists in children's cancers, a team approach that "twins" Rwandan physicians with Boston-based pediatric oncologists has shown it can deliver expert, curative care to young patients stricken with lymphoma.
Scientists at Dana-Farber Cancer Institute have created a "cocktail" of immune-stimulating peptides they believe could provoke the body's defenses to attack multiple myeloma in its early "smoldering" phase and slow or prevent the blood cancer.
A therapy involving a natural compound may improve the ability of stem cells from umbilical cord blood to engraft in patients receiving a stem cell transplant for cancer or other diseases, a phase I clinical trial led by Dana-Farber Cancer Institute scientists indicates.
Scientists at Dana-Farber Cancer Institute have identified a gene mutation that underlies the vast majority of cases of Waldenstrom's macroglobulinemia, a rare form of lymphoma that has eluded all previous efforts to find a genetic cause.
- A volcanic mudflow.